uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03, FiscalAI reports. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.24 million.

Here are the key takeaways from uniQure’s conference call:

• uniQure has a scheduled Type B meeting with the FDA later this quarter to discuss the statistical analysis plan for the 4‑year AMT‑130 data and design elements of a new study, and plans a MAA submission in the U.K. in Q3 based on 3‑year data, creating near‑term regulatory catalysts.
• Enrollment in the Phase I/II‑A study of AMT‑260 for refractory mesial temporal lobe epilepsy is on track, with safety, tolerability and seizure‑frequency results from the first 6‑patient cohort (≥6 months) expected in Q2 and the company targeting a meaningful seizure‑reduction signal to guide dose selection.
• AMT‑191 (Fabry) showed dose‑dependent, durable increases in alpha‑gal A and all 11 dosed patients have discontinued enzyme replacement therapy, but dosing at mid/high cohorts was paused after two asymptomatic grade‑3 liver enzyme elevations and the program is continuing follow‑up while dosing at the low dose.
• The company has discontinued development of AMT‑162 for SOD1‑ALS after a serious adverse event of dorsal root ganglia toxicity in one patient, and will continue safety follow‑up for the five dosed patients.
• uniQure ended Q1 with $586.6 million in cash, equivalents and investments and states this is sufficient to fund operations into H2 2029, though management noted future prioritization will be required to preserve the runway.

uniQure Trading Up 6.3%

Shares of QURE stock traded up $1.34 on Wednesday, hitting $22.50. The stock had a trading volume of 2,129,655 shares, compared to its average volume of 2,827,691. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50. The firm has a market cap of $1.42 billion, a P/E ratio of -6.52 and a beta of 0.87. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average price of $16.70 and a two-hundred day moving average price of $25.23.

Insider Activity

In other news, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the completion of the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at $2,052,823.86. The trade was a 5.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 14,581 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,396 shares of company stock valued at $722,734 in the last quarter. Company insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC acquired a new position in uniQure in the 3rd quarter worth $50,000. Smartleaf Asset Management LLC acquired a new position in uniQure in the 4th quarter worth $48,000. Ensign Peak Advisors Inc boosted its stake in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares during the period. Knott David M Jr boosted its stake in uniQure by 100.0% in the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 2,000 shares during the period. Finally, Deutsche Bank AG boosted its stake in uniQure by 98.3% in the 4th quarter. Deutsche Bank AG now owns 4,621 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 2,291 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on QURE shares. Leerink Partners restated an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Barclays dropped their price objective on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Monday, March 23rd. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research report on Tuesday. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.